Pharmaceutical nanocarriers in treatment and imaging of infection

Nanoparticulates as Drug Carriers

Volumn , Issue , 2006, Pages 697-711

  Schiffelers, Raymond M ^a   Storm, Gert ^a   Bakker Woudenberg, Irma A J M ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NANO-CARRIERS;

EID: 38349107158     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9781860949074_0029     Document Type: Chapter

References (66)

1. Allen TM and Cullis PR (2004) Drug delivery systems: Entering the mainstream. Science 303(5665):1818-1822.
2. Kubik T, Bogunia-Kubik K and Sugisaka M (2005) Nanotechnology on duty in medical applications. Curr Pharm Biotechnol 6(1):17-33.
3. Emerich DF (2005) Nanomedicine - Prospective therapeutic and diagnostic applications. Exp Opin Biol Ther 5(1):1-5.
4. Smith AL (2002) Inhaled antibiotic therapy: What drug? What dose? What regimen? What formulation? J Cyst Firos 1(Suppl 2):189-193.
5. Nissim A, Gofur Y, Vessillier S, Adams G and Chernajovsky Y (2004) Methods for targeting biologicals to specific disease sites. Trends Mol Med 10(6):269-274.
6. Conway SP, Brownlee KG, Denton M and Peckham DG (2003) Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. Am J Respir Med 2(4):321-332.
7. Patel HM (1992) Serum opsonins and liposomes: Their interaction and opsonophagocy-tosis. Crit Rev Ther Drug Carr Syst 9(1):39-90.
8. Szebeni J (1998) The interaction of liposomes with the complement system. Crit Rev Ther Drug Carrier Syst 15(1):57-88.
9. Bradley AJ and Devine DV (1998) The complement system in liposome clearance: Can complement deposition be inhibited? Adv Drug Del Rev 32(1-2):19-29.
10. van de Vosse E, Hoeve MA and Ottenhoff TH (2004) Human genetics of intracellular infectious diseases: Molecular and cellular immunity against mycobacteria and salmonellae. Lancet Inject Dis 4(12):739-749.
11. Dussurget O, Pizarro-Cerda J and Cossart P (2004) Molecular determinants of Listeria monocytogenes virulence. Annu Rev Microbiol 58:587-610.
12. Hueffer K and Galan JE (2004) Salmonella-induced macrophage death: Multiple mechanisms, different outcomes. Cell Microbiol 6(11):1019-1025.
13. Soldati D, Foth BJ and Cowman AF (2004) Molecular and functional aspects of parasite invasion. Trends Parasitol 20(12):567-574.
14. New RR, Chance ML, Thomas SC and Peters W (1978) Antileishmanial activity of anti-monials entrapped in liposomes. Nature 272(5648):55-56.
15. Goldsmith DR and Perry CM (2004) Amphotericin B lipid complex: In visceral leishmaniasis. Drugs 64(17):1905-1911.
16. Veerareddy PR and Vobalaboina V (2004) Lipid-based formulations of amphotericin B. Drugs Today 40(2):133-145.
17. Choi CM and Lerner EA (2002) Leishmaniasis: Recognition and management with a focus on the immunocompromised patient. Am J Clin Dermatol 3(2):91-105.
18. Melby PC (2002) Recent developments in leishmaniasis. Curr Opin Infect Dis 15(5): 485-490.
19. Barrett JP, Vardulaki KA, Conlon C, et al. (2003) A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 25(5):1295-1320.
20. Veerareddy PR, Vobalaboina V and Nahid A (2004) Formulation and evaluation of oil-in-water emulsions of piperine in visceral leishmaniasis. Pharmazie 59(3):194-197.
21. Moghimi SM (2002) Liposome recognition by resident and newly recruited murine liver macrophages. J Lipos Res 12(1-2):67-70.
22. Afrin F, Dey T, Anam K and Ali N (2001) Leishmanicidal activity of stearylamine-bearing liposomes in vitro, j Parasitol 87(1):188-193.
23. Tempone AG, Perez D, Rath S, Vilarinho AL, Mortara RA and de Andrade HF, Jr (2004) Targeting Leishmania (L.) chagasi amastigotes through macrophage scavenger receptors: The use of drugs entrapped in liposomes containing phosphatidylserine. J Antimicrob Chemother 54(1):60-68.
24. Khan MA, Jabeen R, Nasti TH and Mohammad O (2005) Enhanced anticryptococcal activity of chloroquine in phosphatidylserine-containing liposomes in a murine model. J Antimicrob Chemother 55(2):223-228.
25. Medda S, Jaisankar P, Manna RK, Pal B, Giri VS and Basu MK (2003) Phospholipid microspheres: Anovel delivery mode for targeting antileishmanial agent in experimental leishmaniasis. J Drug Targ 11(2):123-128.
26. Datta N, Mukherjee S, Das L and Das PK (2003) Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation. Eur J Immunol 33(6):1508-1518.
27. Khan MA, Nasti TH, Saima K, et al. (2004) Co-administration of immunomodulator tuftsin and liposomised nystatin can combat less susceptible Candida albicans infection in temporarily neutropenic mice. FEMS Immunol Med Microbiol 41(3):249-258.
28. Khan MA, Syed FM, Nasti HT, et al. (2003) Use of tuftsin bearing nystatin liposomes against an isolate of Candida albicans showing less in vivo susceptibility to amphotericin B. J Drug Targ 11(2):93-99.
29. Oettinger C and D’Souza M (2003) Microencapsulation of tumor necrosis factor oligomers: A new approach to proinflammatory cytokine inhibition. J Interf Cytok Res 23(9):533-543.
30. Sioud M and Sorensen DR (2003) Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun 312(4):1220-1225.
31. Bakker-Woudenberg IA (2002) Long-circulating sterically stabilized liposomes as carriers of agents for treatment of infection or for imaging infectious foci. Int J Antimicrob Agents 19(4):299-311.
32. Woodle MC (1998) Controlling liposome blood clearance by surface-grafted polymers. Adv Drug Del Rev 32(1-2):139-152.
33. Moghimi SM and Szebeni J (2003) Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lip Res 42(6):463-478.
34. Ishida T, Harashima H and Kiwada H (2002) Liposome clearance. Biosci Rep 22(2): 197-224.
35. Kaim AH, Jundt G, Wischer T, et al. (2003) Functional-morphologic MR imaging with ultrasmall superparamagnetic particles of iron oxide in acute and chronic soft-tissue infection: Study in rats. Radiology 227(1):169-174.
36. Kaim AH, Wischer T, O’Reilly T, et al. (2002) MR imaging with ultrasmall superparamagnetic iron oxide particles in experimental soft-tissue infections in rats. Radiology 225(3):808-814.
37. Boerman OC, Rennen H, Oyen WJ and Corstens FH (2001) Radiopharmaceuticals to image infection and inflammation. Semin Nucl Med 31(4):286-295.
38. Lutz AM, Weishaupt D, Persohn E, et al. (2005) Imaging of macrophages in soft-tissue infection in rats: Relationship between ultrasmall superparamagnetic iron oxide dose and MR signal characteristics. Radiology 234(3):765-775.
39. Ercan MT and Kostakoglu L (2000) Radiopharmaceuticals for the visualization of infectious and inflammatory lesions. Curr Pharm Des 6(11):1159-1177.
40. Becker MJ, Dams ET, de Marie S, et al. (2002) Scintigraphic imaging using 99mTc-labeled PEG liposomes allows early detection of experimental invasive pulmonary aspergillosis in neutropenic rats. Nucl Med Biol 29(2):177-184.
41. Laverman P, Zalipsky S, Oyen WJ, et al. (2000) Improved imaging of infections by avidin-induced clearance of 99mTc-biotin-PEG liposomes. J Nucl Med 41(5):912-918.
42. Schiffelers R, Storm G and Bakker-Woudenberg I (2001) Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. J Antimicrob Chemother 48(3):333-344.
43. Maurer N, Fenske DB and Cullis PR (2001) Developments in liposomal drug delivery systems. Exp Opin Biol Ther 1(6):923-947.
44. Schiffelers RM, Bakker-Woudenberg IA and Storm G (2000) Localization of sterically stabilized liposomes in experimental rat Klebsiella pneumoniae pneumonia: Dependence on circulation kinetics and presence of poly(ethylene)glycol coating. Biochim Biophys Acta 1468(1-2):253-261.
45. Schiffelers RM, Bakker-Woudenberg IA, Snijders SV and Storm G (1999) Localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue: Influence of liposome characteristics. Biochim Biophys Acta 1421(2):329-339.
46. Schiffelers RM, Storm G and Bakker-Woudenberg IA (2001) Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue. Pharm Res 18(6):780-787.
47. Bakker-Woudenberg IA, Schiffelers RM, Storm G, Becker MJ and Guo L (2005) Long-circulating sterically stabilized liposomes in the treatment of infections. Meth Enzymol 391:228-260.
48. Schiffelers RM, Storm G, ten Kate MT and Bakker-Woudenberg IA (2001) Therapeutic efficacy of liposome-encapsulated gentamicin in rat Klebsiella pneumoniae pneumonia in relation to impaired host defense and low bacterial susceptibility to gentamicin. Antimicrob Agents Chemother 45(2):464-170.
49. Schiffelers RM, Storm G, ten Kate MT, et al. (2001) In vivo synergistic interaction of liposome-coencapsulated gentamicin and ceftazidime. J Pharmacol Exp Ther 298(1): 369-375.
50. Labana S, Pandey R, Sharma S and Khuller GK (2002) Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. Int J Antimicrob Agents 20(4):301-304.
51. Kadry AA, Al-Suwayeh SA, Abd-Allah AR and Bayomi MA (2004) Treatment of experimental osteomyelitis by liposomal antibiotics. J Antimicrob Chemother 54(6): 1103-1108.
52. Bakker-Woudenberg IA, ten Kate MT, Guo L, Working P and Mouton JW (2002) Ciprofloxacin in polyethylene glycol-coated liposomes: Efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection. Antimicrob Agents Chemother 46(8): 2575-2581.
53. Bakker-Woudenberg IA, ten Kate MT, Guo L, Working P and Mouton JW (2001) Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats. Antimicrob Agents Chemother 45(5):1487-1492.
54. Espuelas MS, Legrand P, Campanero MA, et al. (2003) Polymeric carriers for amphotericin B: In vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice. J Antimicrob Chemother 52(3):419-427.
55. Fukui H, Koike T, Saheki A, Sonoke S and Seki J (2003) A novel delivery system for amphotericin B with lipid nano-sphere (LNS). Int J Pharm 265(1-2):37-45.
56. Clemons KV, Ranney DF and Stevens DA (2001) A novel heparin-coated hydrophilic preparation of amphotericin B hydrosomes. Curr Opin Investig Drugs 2(4):480-487.
57. Dale RM, Schnell G and Wong JP (2004) Therapeutic efficacy of “nubiotics” against burn wound infection by pseudomonas aeruginosa. Antimicrob Agents Chemother 48(8): 2918-2923.
58. Zhang W, Yang H, Kong X, et al. (2005) Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med 11(1):56-62.
59. Zheng X and Bevilacqua PC (2004) Activation of the protein kinase PKR by short doublestranded RNAs with single-stranded tails. Rna 10(12):1934-1945.
60. Sledz CA and Williams BR (2004) RNA interference and double-stranded-RNA-activated pathways. Biochem Soc Trans 32(Pt 6):952-956.
61. Wong JP, Nagata LP, Christopher ME, Salazar AM and Dale RM (2005) Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs. Vaccine 23 (17-18):2266-2268.
62. Umamaheshwari RB, Ramteke S and Jain NK (2004) Anti-Helicobacter pylori effect of mucoadhesive nanoparticles bearing amoxicillin in experimental gerbils model. AAPS PharmSciTech 5(2):e32.
63. Umamaheshwari RB, Jain S, Bhadra D and Jain NK (2003) Floating microspheres bearing acetohydroxamic acid for the treatment of helicobacter pylori. J Pharm Pharmacol 55(12):1607-1613.
64. Umamaheshwari RB and Jain NK (2004) Receptor-mediated targeting of lipobeads bearing acetohydroxamic acid for eradication of helicobacter pylori. J Control Rel 99(1):27-40.
65. Wong JP, Yang H, Blasetti KL, Schnell G, Conley J and Schofield LN (2003) Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J Control Rel 92(3):265-273.
66. Marier JF, Brazier JL, Lavigne J and Ducharme MP (2003) Liposomal tobramycin against pulmonary infections of pseudomonas aeruginosa: A pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. J Antimicrob Chemother 52(2):247-252.